Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Shenghuo Completes Restatement; Issues Q3 Report

publication date: Nov 21, 2008

China Shenghuo Pharmaceutical Holdings (昆明圣火药业（集团）有限公司) released its Q3 financial report and also announced that it has completed restatement of financial results for 2007 and the first two quarters of 2008. Most notable was the restatement in 2007’s net income, which dropped by a very significant $2.3 million, taking it down to $1.7 million.  In Q3, revenues climbed 73%, but net income dropped.  More details...

Stock Symbol: (AMEX: KUN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital